CONBA (600572.SH) subsidiary obtains drug registration certificate for dapoxetine hydrochloride tablets

Zhitong Finance APP News, Conba (600572.SH) announced that recently, its wholly-owned subsidiary Hangzhou Conba Pharmaceutical Co., Ltd. received the "Drug Registration Certificate" for dapoxetine hydrochloride tablets in two specifications (specifications: 30mg, 60mg) approved and issued by the National Medical Products Administration. Dapoxetine hydrochloride tablets are a short-acting selective serotonin reuptake inhibitor, clinically indicated for the treatment of premature ejaculation (PE) in male patients aged 18 to 64, featuring rapid absorption, fast onset of action, and a short half-life, with good safety and tolerability. The drug was approved as a Class 4 chemical drug, and is deemed to have passed the generic drug consistency evaluation.